Nucleai
Klaas Zuideveld currently serves as the Chief Executive Officer and Chief Development Officer at Versameb AG since May 2020, while also contributing as a member of the Advisory Board at Nucleai and as an Advisor at Bulb Healthcare Solutions. Notable past roles include Vice President of Pharma Partnerships at Caris Life Sciences from April 2016 to April 2020 and various positions at F. Hoffmann-La Roche Ltd. from October 2002 to September 2014, culminating as Project Leader. Earlier experience includes a consultancy role at Pharsight (Certara). Educational credentials comprise an MSc in Biopharmaceutical Sciences and a PhD in Pharmacology and Mathematics from Leiden University.
This person is not in any teams
This person is not in any offices
Nucleai
7 followers
Nucleai is a spatial biology company that has developed an AI-powered platform to enhance drug development and improve patient outcomes. Nucleai’s platform leverages unique tissue datasets to produce insights into cancer biology, increasing clinical trial efficacy and improving patient care. Nucleai works with leading pharmaceutical companies,licensing its research platform for internal use, and collaborating in biomarkers discovery projects.